NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.


[profilepress-login id="1"]

Don't have an account? Subscribe

ADVERTISEMENT

HIQA recommends change to BCG vaccination strategy

By Dermot - 08th Dec 2015

The recommendation is part of a health technology assessment published today. The assessment also advises that any change in strategy must be supported “by a clear commitment to enhanced systematic and comprehensive tuberculosis (TB) control measures.”

“A recommendation to switch to a policy of selective neonatal vaccination has been made based on the best available evidence,” said HIQA’s Director of Health Technology Assessment Dr Máirín Ryan.

“However, this is only recommended if appropriate preventative and protective measures are in place.

“If selective vaccination is adopted, the most efficient method of delivering the programme needs to be determined to ensure best use of available resources and to minimise the impact of discontinuing universal vaccination.”

HIQA’s health technology assessment advises that sufficient resources for enhanced TB control and public awareness efforts must be provided before there is any change in national vaccination policy and strategy.

“Selective vaccination would focus resources on those who are at higher risk of contracting TB; one in eight newborns will continue to be eligible for the vaccine.”

ADVERTISEMENT

Latest

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT